Skip to Content

Zolinza Approval History

FDA Approved: Yes (First approved October 6, 2006)
Brand name: Zolinza
Generic name: vorinostat
Dosage form: Capsules
Company: Merck & Co., Inc.
Treatment for: Cutaneous T-cell Lymphoma

Zolinza (vorinostat) is a histone deacetylase (HDAC) inhibitor for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL), a form of non-Hodgkin's lymphoma, who have progressive, persistent or recurrent disease on or following two systemic therapies.

Development History and FDA Approval Process for Zolinza

DateArticle
Oct  6, 2006Approval Zolinza Merck & Co., Inc. - Treatment for Cutaneous T-cell Lymphoma
Jun  7, 2006Zolinza, Merck's Investigational Medicine for Advanced Cutaneous T-Cell Lymphoma (CTCL), to Receive Priority Review from U.S. Food and Drug Administration

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide